120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
血清同型半胱氨酸作为阿尔茨海默病分期和进展监测的潜在动态生物标志物
Authors Wu C , Wu C, Yin X, Zhong C
Received 12 July 2025
Accepted for publication 13 January 2026
Published 21 January 2026 Volume 2026:22 553269
DOI https://doi.org/10.2147/NDT.S553269
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Roger Pinder
Cong Wu,1 Chunli Wu,2 Xiaoyu Yin,2 Changyang Zhong2
1The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People’s Republic of China; 2Cerebrovascular Disease Department, Hangzhou Third People’s Hospital, Hangzhou, Zhejiang, People’s Republic of China
Correspondence: Changyang Zhong, Department of Cerebrovascular Disease, Hangzhou Third People’s Hospital, Hangzhou, Zhejiang, 310009, People’s Republic of China, Email zhonghening@163.com
Background: Reliable biomarkers are urgently needed for the early diagnosis and dynamic monitoring of Alzheimer’s disease (AD). Serum homocysteine (Hcy) has been increasingly investigated but with inconsistent association to AD severity.
Objective: To investigate the correlation between serum Hcy levels and AD severity/cognitive function, and to evaluate its clinical utility as a dynamic monitoring indicator for the disease.
Methods: This retrospective study enrolled 80 AD patients (stratified by Mini-Mental State Examination [MMSE] score: 40 mild, 28 moderate, 12 severe) and 80 healthy controls from the Cerebrovascular Disease outpatient and inpatient departments of our hospital between January 2022 and December 2024. Fasting serum Hcy was measured via chemiluminescent immunoassay. Correlation with cognitive scores and severity discrimination were analyzed.
Results: Serum Hcy levels were significantly higher in the AD group than controls (21.2 ± 6.6 vs 14.5 ± 4.8 μmol/L, p < 0.05), increasing with severity (mild: 16.8 ± 3.2, moderate: 21.2 ± 4.5, severe: 25.6 ± 5.8 μmol/L, p < 0.001). A strong inverse correlation with MoCA scores was observed (r = − 0.76, p < 0.01). ROC analysis showed an AUC of 0.87 for discriminating AD severity, with an optimal cut-off of 17.5 μmol/L (sensitivity 78%, specificity 72%). After 6 months of B-vitamin intervention, Hcy decreased significantly with cognitive improvement.
Conclusion: Serum Hcy correlates strongly with AD severity and cognitive decline, supporting its potential as a dynamic biomarker for monitoring progression and treatment response.
Keywords: Alzheimer’s disease, homocysteine, cognitive decline, biomarker, dynamic monitoring
1The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People’s Republic of China; 2Cerebrovascular Disease Department, Hangzhou Third People’s Hospital, Hangzhou, Zhejiang, People’s Republic of China
Correspondence: Changyang Zhong, Department of Cerebrovascular Disease, Hangzhou Third People’s Hospital, Hangzhou, Zhejiang, 310009, People’s Republic of China, Email zhonghening@163.com
Background: Reliable biomarkers are urgently needed for the early diagnosis and dynamic monitoring of Alzheimer’s disease (AD). Serum homocysteine (Hcy) has been increasingly investigated but with inconsistent association to AD severity.
Objective: To investigate the correlation between serum Hcy levels and AD severity/cognitive function, and to evaluate its clinical utility as a dynamic monitoring indicator for the disease.
Methods: This retrospective study enrolled 80 AD patients (stratified by Mini-Mental State Examination [MMSE] score: 40 mild, 28 moderate, 12 severe) and 80 healthy controls from the Cerebrovascular Disease outpatient and inpatient departments of our hospital between January 2022 and December 2024. Fasting serum Hcy was measured via chemiluminescent immunoassay. Correlation with cognitive scores and severity discrimination were analyzed.
Results: Serum Hcy levels were significantly higher in the AD group than controls (21.2 ± 6.6 vs 14.5 ± 4.8 μmol/L, p < 0.05), increasing with severity (mild: 16.8 ± 3.2, moderate: 21.2 ± 4.5, severe: 25.6 ± 5.8 μmol/L, p < 0.001). A strong inverse correlation with MoCA scores was observed (r = − 0.76, p < 0.01). ROC analysis showed an AUC of 0.87 for discriminating AD severity, with an optimal cut-off of 17.5 μmol/L (sensitivity 78%, specificity 72%). After 6 months of B-vitamin intervention, Hcy decreased significantly with cognitive improvement.
Conclusion: Serum Hcy correlates strongly with AD severity and cognitive decline, supporting its potential as a dynamic biomarker for monitoring progression and treatment response.
Keywords: Alzheimer’s disease, homocysteine, cognitive decline, biomarker, dynamic monitoring